178 related articles for article (PubMed ID: 38108984)
41. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
[TBL] [Abstract][Full Text] [Related]
42. Impact of temozolomide on immune response during malignant glioma chemotherapy.
Sengupta S; Marrinan J; Frishman C; Sampath P
Clin Dev Immunol; 2012; 2012():831090. PubMed ID: 23133490
[TBL] [Abstract][Full Text] [Related]
43. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Everaert E; Neyns B; Joosens E; Strauven T; Branle F; Menten J
J Neurooncol; 2004 Oct; 70(1):37-48. PubMed ID: 15527106
[TBL] [Abstract][Full Text] [Related]
44. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
Faustino AC; Viani GA; Hamamura AC
Clinics (Sao Paulo); 2020; 75():e1553. PubMed ID: 32935821
[TBL] [Abstract][Full Text] [Related]
45. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
[TBL] [Abstract][Full Text] [Related]
46. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
[TBL] [Abstract][Full Text] [Related]
47. Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution.
Chiang KL; Chang KP; Lee YY; Huang PI; Hsu TR; Chen YW; Chang FC; Wong TT
Childs Nerv Syst; 2010 Aug; 26(8):1035-41. PubMed ID: 20217098
[TBL] [Abstract][Full Text] [Related]
48. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Chamberlain MC; Glantz MJ
J Neurooncol; 2008 Sep; 89(2):231-8. PubMed ID: 18480965
[TBL] [Abstract][Full Text] [Related]
49. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Lee EQ; Puduvalli VK; Reid JM; Kuhn JG; Lamborn KR; Cloughesy TF; Chang SM; Drappatz J; Yung WK; Gilbert MR; Robins HI; Lieberman FS; Lassman AB; McGovern RM; Xu J; Desideri S; Ye X; Ames MM; Espinoza-Delgado I; Prados MD; Wen PY
Clin Cancer Res; 2012 Nov; 18(21):6032-9. PubMed ID: 22923449
[TBL] [Abstract][Full Text] [Related]
50. Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Yao H; Liu J; Zhang C; Shao Y; Li X; Feng M; Wang X; Gan W; Zhou Y; Huang Y
J Clin Neurosci; 2021 Aug; 90():82-88. PubMed ID: 34275586
[TBL] [Abstract][Full Text] [Related]
51. Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Froklage FE; Oosterbaan LJ; Sizoo EM; de Groot M; Bosma I; Sanchez E; Douw L; Heimans JJ; Reijneveld JC; Lagerwaard FJ; Buter J; Uitdehaag BM; Klein M; Postma TJ
J Neurooncol; 2014 Jan; 116(2):387-94. PubMed ID: 24264531
[TBL] [Abstract][Full Text] [Related]
52. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A
Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
[TBL] [Abstract][Full Text] [Related]
53. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
van den Bent MJ; Taphoorn MJ; Brandes AA; Menten J; Stupp R; Frenay M; Chinot O; Kros JM; van der Rijt CC; Vecht ChJ; Allgeier A; Gorlia T;
J Clin Oncol; 2003 Jul; 21(13):2525-8. PubMed ID: 12829671
[TBL] [Abstract][Full Text] [Related]
54. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Gupta T; Mohanty S; Moiyadi A; Jalali R
Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
[TBL] [Abstract][Full Text] [Related]
55. PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Beppu T; Iwaya T; Sato Y; Nomura JI; Terasaki K; Sasaki T; Yamada N; Fujiwara S; Sugai T; Ogasawara K
Clin Nucl Med; 2022 Jul; 47(7):569-574. PubMed ID: 35452002
[TBL] [Abstract][Full Text] [Related]
56. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
57. Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Guillevin R; Menuel C; Taillibert S; Capelle L; Costalat R; Abud L; Habas C; De Marco G; Hoang-Xuan K; Chiras J; Vallée JN
Br J Cancer; 2011 Jun; 104(12):1854-61. PubMed ID: 21610707
[TBL] [Abstract][Full Text] [Related]
58. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A
J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723
[TBL] [Abstract][Full Text] [Related]
59. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Rizzo D; Scalzone M; Ruggiero A; Maurizi P; Attinà G; Mastrangelo S; Lazzareschi I; Ridola V; Colosimo C; Caldarelli M; Balducci M; Riccardi R
J Chemother; 2015 Feb; 27(2):106-10. PubMed ID: 25466729
[TBL] [Abstract][Full Text] [Related]
60. Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
Liu Y; Feng F; Ji P; Liu B; Ge S; Yang C; Lou M; Liu J; Li B; Gao G; Qu Y; Wang L
Clin Neurol Neurosurg; 2018 Jun; 169():64-70. PubMed ID: 29631109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
